Mikael Dolsten: Yeah, I can just echo what you said so well, Albert. We and I remain very enthusiastic to look forward, to see the data. We have not seen the final top line report coming out. So today, the study is still ongoing but will be available before year-end. Danuglipron has shown, as you know, some really interesting profile as a full agonist and it’s our main opportunity and effort for obesity and Type 2 diabetes. We got earlier today a question about new molecules that are coming in. And that’s when I mentioned that our additional indications to pursue for such new molecules and we’ll also have new mechanisms that are validated that’s coming in in oral version. So it just punctuates our big effort we have around both these class and obesity and other disorders.
Albert Bourla: In essence, he’s still excited.
Operator: Next, we have Louise Chen with Cantor.
Louise Chen: I wanted to ask you on this fourth generation PCV, how much additional serotype coverage will you have? And then, also on ABRYSVO, will that be available to pregnant women in the pharmacy? Or do they have to go to their OBGYN? And then lastly, just on danuglipron again, here, will you also have the modified release data before year-end.
Albert Bourla: Monadelphous, you want to take the PCV question and danu, but also, Angela, very quickly, ABRYSVO is available at the pharmacy.
Angela Hwang: Yes, it’s going to be available in pharmacies and doctors’ offices and OBGYN offices. I think we have a real stocking advantage here, Louise, because anyone just needs to stock one product for two indications for both populations. So I think the uptake is to come. And certainly, the next few months, being that it’s the winter, is when we begin to – we believe we’ll see some good uptake.
Mikael Dolsten: On the PCV fourth generation, I hope you looked at today’s data. And what you could see is that we are really the first company that have been able to put in place a whole set of new technology that can bring immune responses to a higher level than have been seen and that allow us to go with even more comprehensive coverage than the current 20. I’m not going to give your curiosity an answer how many serotype. I can just tell you it’s considerable more than the 20. On danu, we look upon danuglipron as the once-a-day QD molecule because of the reformulation technologies that were put in place and already generated some clinical data on and are now concluding. So that’s really how we look upon danuglipron and we’ll have final data on the best formulation option early next year. But as Albert said, we’re enthusiastic to look forward to the efficacy data later this year. So very exciting time.
Operator: Next, we have David Risinger with Leerink Partners.
David Risinger: I have another question on danuglipron since it appears to be the company’s number one pipeline candidate based upon your forecasts. So regarding the Phase 2b results that are expected soon, how should we expect Pfizer to share those results? And then, with regard to the once daily formulation that you just mentioned, Mikael, will that be ready for the Phase 3 start assuming that the company moves to start Phase 3 shortly after the Phase 2b results are generated?
Albert Bourla: The first question, given the importance [indiscernible]. But with a press release, we’ve made them publicly available. Now, Mikael, you want to take the second part of the question of David?
Mikael Dolsten: Yeah, I can first echo what Albert and I said, we look forward with enthusiasm to get the danuglipron obesity data later this year. And of course, as Albert said, pending totality of reviewing everything we have, we have made a lot of progress and been able to accelerate the QD danu. Now, we’re waiting for some more clinical data early next year, but I think it’s within our reach. If we decide to do, to start the pivotal study next year to do it with an once a day molecule.
Operator: Next, we have Chris Schott with J.P. Morgan.
Chris Schott: Just two for me here. First, can you just comment a little bit more on what we’re seeing with Nurtec and the ramp relative to your expectations? And maybe just as part of that, just any color on pricing we’re seeing within the market today and how we should think about that going forward. And then my second question was on 2024. I know you’re not giving guidance today. But as you look at where consensus has kind of shaken out post the COVID and cost restructuring updates, and if the earnings are in kind of low $3 range at this point, I guess just are there any directional kind of pushes or pulls in the numbers that you feel the Street isn’t capturing properly and should be kind of thinking about before we get your kind of formal guidance as we look to early next year?
Dave Denton: Obviously, it’s a little over 2024. I would just say that, clearly, we had a clearing event as it relates to our COVID expectations for this year. So a lot of that risk is behind us as we think about the balance this year. I do expect that the balance of this year will be very informative, particularly in the US as we think about utilization trends, both for vaccination rates, importantly Paxlovid, here in the US that will allow us to have a better clarity as we cycle into 2024 of the utilization around those specific products, which will still be meaningful to us at an enterprise level. Clearly, when we get to providing guidance, we’ll give you a lot of information beneath that, so you can get a good sense of our – importantly, our non-COVID products which continue to trend very favorably and very well.
And we can layer on, I’ll say, the optionality associated with our COVID franchise as we cycle into next year. So, obviously, a lot more to come. We’re looking forward to sharing those very specific details after the first of the year.
Mark Southey: And then, Angela, about Nurtec launch – not launch, about the Nurtec performance in the marketplace, including the price.
Angela Hwang: Thanks for the question, Chris, because it’s a great opportunity for us to share that we are seeing Nurtec perform just as we expected. In fact, with some really strong performance indicators that I’d like to share with you. First of all, from a TRx perspective, we grew 28% compared to last year this time, and sequentially, we grew 6% versus last quarter. In fact, on October 20, we saw the highest week of TRx’s and NRxs to date. That growth is also seen in the number of prescribers. Just this quarter alone, we had 73,000 prescribers writing Nurtec. And we are now moving at a clip of about 23,000 writer a week which is 30% more than Ubrelvy and double that of Qulipta. Another good place to look is also in new to brand starts, right, NBRxs.
And when you look at that, NBRx growth for Nurtec is higher than Ubrelvy and Qulipta in all the deciles of physicians, but particularly in the decile 8 to 10, which, as you know, is where the highest prescribers are or who are the highest prescribers. And then, when you look at pill count, we see something interesting there too. We have been very intensely or intently driving our pill pack toward the larger pill pack size, which is the 16 pack because of our prevention indication. And so, when you look at the totality of all the pills or the total volume of pills, we have a leading market share there, more than 50%. And so, I think when you look at all these indicators, at least from the way that we’re looking at it, it’s very positive story.
It’s exactly how we see it. The expansion into primary care, as you heard in Albert’s comments, is what it is that we’re after. And today, only 17% of the entire market is oral CGRPs, which tells you that most of the market is still an opportunity for us and represents growth that we’re really, really looking forward to. And I think that we put the right investments in the right places to generate this growth in the future. From a pricing perspective, obviously, it’s a product that is rebated, and so I think the way to think about it is that, from a patient perspective, which is where we really put a lot of focus, we want to make sure that our patients are able to get the scripts, are able to get access for Nurtec, especially as you consider that we’re trying to mobilize people away from Topiramate and away from triptans on to all CGRPs. So the gross to net effects here are significant.
